Johnson & Johnson logo

Johnson & Johnson (JNJ)

Market Closed
5 Jun, 20:00
NYSE NYSE
$
232. 77
+4.6
+2.016%
$
564.11B Market Cap
29.06 P/E Ratio
0.69% Div Yield
5.64M Volume
9.91 Eps
$ 228.17
Previous Close
Add Transaction
Day Range
229 235.21
Year Range
149.04 251.71
Want to track JNJ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors

Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors

Johnson & Johnson (JNJ) reachead $146.18 at the closing of the latest trading day, reflecting a +1.75% change compared to its last close.

Zacks | 1 year ago
2 Dividend Kings to Rule Them All in 2025

2 Dividend Kings to Rule Them All in 2025

If history is any teacher, the best thing you can do with your money is buy dividend stocks.

247wallst | 1 year ago
Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?

Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?

Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks | 1 year ago
Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note

Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note

The latest trading day saw Johnson & Johnson (JNJ) settling at $144.62, representing a +0.89% change from its previous close.

Zacks | 1 year ago
J&J Trading Near 52-Week Low: Should You Sell the Stock?

J&J Trading Near 52-Week Low: Should You Sell the Stock?

Those who own the stock may stay invested for some time as J&J looks optimistic about a better performance in 2025.

Zacks | 1 year ago
Johnson & Johnson Death Cross: Stock Stumbles Despite Pipeline Promise

Johnson & Johnson Death Cross: Stock Stumbles Despite Pipeline Promise

Johnson & Johnson JNJ, the iconic healthcare giant known for its stable dividends and defensive appeal, has entered a bearish technical pattern: the Death Cross.

Benzinga | 1 year ago
JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723

JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723

Johnson & Johnson announces a global licensing deal with Kaken for the latter's eczema candidate, KP-723, to further strengthen its dermatology portfolio.

Zacks | 1 year ago
US FDA proposes standardized testing to detect asbestos in talc products

US FDA proposes standardized testing to detect asbestos in talc products

The U.S. Food and Drug Administration is proposing that cosmetic products containing talc should be tested using standardized methods to detect asbestos, a potential contaminant, according to documents posted on the federal register on Thursday.

Reuters | 1 year ago
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Zacks | 1 year ago
Give Yourself the Gift That Will Keep On Giving in 2025 and Buy These 3 Top Dividend Stocks

Give Yourself the Gift That Will Keep On Giving in 2025 and Buy These 3 Top Dividend Stocks

Dividend-paying stocks are the gift that keeps on giving. They pay you a recurring stream of passive income that you can use to make new investments or cover some of your expenses.

Fool | 1 year ago
Johnson & Johnson (JNJ) Ascends But Remains Behind Market: Some Facts to Note

Johnson & Johnson (JNJ) Ascends But Remains Behind Market: Some Facts to Note

In the most recent trading session, Johnson & Johnson (JNJ) closed at $145.27, indicating a +0.55% shift from the previous trading day.

Zacks | 1 year ago
Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Zacks | 1 year ago
Loading...
Load More